首页|?FLT3-ITD Mutation Does Not Influence Survival Outcome in Adult Acute Promyelocytic Leukemia Patients Treated With ATO and ATRA-Based Therapeutic Regimen: Experience From a North Indian Tertiary Care Centre?
?FLT3-ITD Mutation Does Not Influence Survival Outcome in Adult Acute Promyelocytic Leukemia Patients Treated With ATO and ATRA-Based Therapeutic Regimen: Experience From a North Indian Tertiary Care Centre?
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Cig Media Group, Lp
FLT3-ITD was frequent in adult acute promyelocytic leukemia cases although its presence did not influence the treatment outcome in an arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) based therapeutic regimen. However, its presence was associated with predictors of inferior survival outcome like leukocytosis and BCR3 transcript type. Introduction: NPM1 and FLT3 -ITD are frequently mutated genes in acute myeloid leukemia. We studied clinicohematological profile and survival outcome of adult acute promyelocytic leukemia (APL) patients harboring these mutations. Materials and Methods: De novo APL cases ( > 12 years), enrolled between January 2019 and June 2020, were evaluated for FLT3 -ITD and NPM1 mutations (A, B, D mutations) by conventional and real-time qualitative PCR respectively. Results: FLT3 -ITD mutation was detected in 12 of 36 (33.3%) de novo APLs cases while NPM1 mutation was not detected. FLT3 -ITD was more frequently associated with Sanz high-risk category as compared to the intermediate-risk category (75% vs. 29%, P = .02), with BCR3 transcript type ( P = .08) and higher median WBC count [22.7 ?? 10 9 /L)(range 1.3-184), P = .018]. One and half-years overall survival (OS) and event-free survival (EFS) were not significantly altered by the presence/absence of FLT3 -ITD mutation (OS 86% vs. 70%, P = .32; EFS 86% vs. 70%, P = .33), between genders (OS, EFS both 89% in males vs. 69% in females, P = .15) and between adolescent and younger adults (AYA) ( ??? 30 years) and older adult APL cases ( > 30 years) (OS 86% vs. 78%, P = .55; EFS 85% vs. 77%, P = .55), however were significantly lower with BCR3 transcript as compared to BCR1 transcript (OS 56% vs. 91%, P = .019; EFS 56% vs. 91%, P = .016) in univariate analysis, although not in multivariate analysis. One and half-year OS and EFS was 57% (6/14, P = .009 for each) in high-risk APL. Conclusion: FLT3 -ITD mutation did not influence survival outcome in adult APL treated with ATO and ATRA-based therapeutic regimen.
Adolescent and young adultsBCR isoformFLT3NPM1Overall survivalTRANS-RETINOIC ACIDINTERNAL TANDEM DUPLICATIONSCONFERS POORIMPACTGENE
NSTL
Cig Media Group, Lp
